Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03794076 · ClinicalTrials.gov registry record · Phase 1
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
A Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by Vishwajit Nimgaonkar, MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT03794076: Recruiting Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by Vishwajit Nimgaonkar, MD PhD.
NCT03794076 is a Phase 1 study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by Vishwajit Nimgaonkar, MD PhD. The registered enrollment target is 160 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03794076, a Phase 1 study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by Vishwajit Nimgaonkar, MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.
Primary Outcome
Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (mi
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cromoglycate
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT03794076 shows while recruiting
NCT03794076 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03794076 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03794076 about?
NCT03794076 is a clinical study titled "Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia". This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.
What is the current status of trial NCT03794076?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2019-04-01. Estimated completion is 2028-06.
What conditions does trial NCT03794076 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT03794076?
The interventions under investigation include: Placebo (DRUG), Cromoglycate (DRUG).
Who is sponsoring clinical trial NCT03794076?
This trial is sponsored by Vishwajit Nimgaonkar, MD PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03794076 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03794076's enrollment target sits among peer trials
160 102nd of 315 higher than 212 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI